Valneva Share: One of the Best Gains on the SBF 120, the Stock Climbs 2.5%
The Lyon-based vaccine laboratory is recovering during the session, against the grain of a declining SBF 120. The share is regaining some ground after a difficult early October, but remains far from its moving averages.
A Rebound of 2.67% That Places Valneva in the Top Three of the SBF 120
The Valneva share gains 2.67% to €2.60 during the session, while the SBF 120 falls 0.9%. It ranks among the strongest gainers on the index, behind Nanobiotix and ID Logistics. This rebound comes after two sessions of decline, including a 2.5% drop on Friday. The overall picture remains mixed: the share is still down 2.3% over a week and 12% over a month, after gaining 11% over three months.
A Price Below Its Three Moving Averages, Testing the Support Level at €2.54
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The share is trading below its 20-day MA (€2.79, variance of 6.9%), its 50-day MA (€2.66) and its 200-day MA (€3.08), which leaves little room for today's rebound. The support at €2.54 lies approximately 2% below the current price, while resistance at €2.99 remains distant. The RSI at 38 reflects weeks of selling pressure, without reaching an oversold zone.
On the fundamentals side, the group confirmed its 2026 outlook upon publishing its first-half results on August 13, 2026, despite the impact of the geopolitical context on travel. The company is also listed on the Nasdaq in the form of ADRs (1 ADR for 2 shares), but Paris accounts for the bulk of trading volumes.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
